Altimmune (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). Please contact us for more information
Our management team has broad expertise across scientific and business operations, inventing compounds and advancing product candidates through clinical development.
Board of Directors
Dr. Jorkasky is a member of the Connecticut Academy of Science and Technology and has been recognized by the Connecticut Women’s Hall of Fame for her scientific leadership and mentoring of young women, as well as the Connecticut Council on Technology for her work in driving technological improvements in clinical research operations.
Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology, having received her medical degree from University of Pennsylvania. She is a Woodrow Wilson Visiting Fellow, on the faculties of University of California, San Francisco and Uniformed Service of Health Sciences Medical Schools, with previous faculty appointments at Yale University and the University of Pennsylvania Schools of Medicine.
We believe strategic partnerships break barriers to innovation and we continuously evaluate partnership opportunities. Contact Jose Ochoa, Chief Business Officer, for partnership inquiries.
For partnership opportunities contact:
Chief Business Officer